We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

91 hedge funds and large institutions have $93.8M invested in Tetraphase Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 30 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% less funds holding

Funds holding: 10191 (-10)

13% less capital invested

Capital invested by funds: $108M → $93.8M (-$13.7M)

17% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 30

38% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 24

68% less call options, than puts

Call options by funds: $139K | Put options by funds: $437K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
91
Holders Change
-10
Holders Change %
-9.9%
% of All Funds
2.43%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
15
Increased
25
Reduced
30
Closed
24
Calls
$139K
Puts
$437K
Net Calls
-$298K
Net Calls Change
-$1.69M
Name Holding Trade Value Shares
Change
Change in
Stake
PPA
51
Parametric Portfolio Associates
Washington
$128K +$137K +1,492 New
Manulife (Manufacturers Life Insurance)
52
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$122K +$14.6K +159 +13%
Dimensional Fund Advisors
53
Dimensional Fund Advisors
Texas
$109K
Morgan Stanley
54
Morgan Stanley
New York
$104K -$144K -1,568 -56%
NFA
55
Nationwide Fund Advisors
Ohio
$104K
TA
56
Teton Advisors
New York
$103K +$110K +1,200 New
BG
57
Bellevue Group
Switzerland
$95K
AIG
58
American International Group
New York
$90K -$7.24K -79 -7%
State Board of Administration of Florida Retirement System
59
State Board of Administration of Florida Retirement System
Florida
$85K
Susquehanna International Group
60
Susquehanna International Group
Pennsylvania
$82K -$435K -4,745 -83%
Connor, Clark & Lunn Investment Management (CC&L)
61
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$75K -$18.3K -200 -19%
VOYA Investment Management
62
VOYA Investment Management
Georgia
$75K
T. Rowe Price Associates
63
T. Rowe Price Associates
Maryland
$73K +$458 +5 +0.6%
BA
64
BlackRock Advisors
Delaware
$71K
Tudor Investment Corp
65
Tudor Investment Corp
Connecticut
$65K -$134K -1,460 -66%
Wells Fargo
66
Wells Fargo
California
$62K -$14.8K -161 -18%
Bank of America
67
Bank of America
North Carolina
$54K +$26.6K +290 +88%
BSW
68
Buckingham Strategic Wealth
Missouri
$51K
PAM
69
Princeton Alpha Management
New Jersey
$45K +$48.5K +529 New
Citigroup
70
Citigroup
New York
$42K -$113K -1,237 -72%
BlackRock
71
BlackRock
New York
$35K +$26.3K +287 +228%
CG
72
Cutler Group
California
$33K -$121K -1,317 -77%
MCM
73
Manchester Capital Management
Vermont
$32K
Legal & General Group
74
Legal & General Group
United Kingdom
$29K
JIC
75
Joel Isaacson & Co
New York
$22K

TTPH Hedge Fund Activity: Q2 2016 in Review

91 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q2 2016, worth a combined $93.8M — down 13% from $108M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of TTPH and 15 opened new positions — a net loss of 9 holders — while 30 trimmed existing stakes and 25 added.

The largest buyer was Wellington Management Group, adding an estimated $5.64M. The largest seller was Great Point Partners, cutting an estimated $6.2M.

  • 91 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q2 2016, down from 101 in Q1 2016.
  • Funds reported $93.8M of Tetraphase Pharmaceuticals, Inc. stock for Q2 2016, down 13% quarter-over-quarter.
  • 15 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q2 2016 and 24 closed out, a net change of -9 holders.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q2 2016 was Wellington Management Group, an estimated $5.64M added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q2 2016 was Great Point Partners, an estimated $6.2M sold.

Based on aggregated 13F filings for Q2 2016.